News | July 23, 2025
Lonza reports 19% growth in sales in H1
Upgrades 2025 full-year CDMO sales and margin outlook
Upgrades 2025 full-year CDMO sales and margin outlook
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
The new Zigly center features and offers comprehensive veterinary services
The company is addressing these observations comprehensively
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
This marks the fourth acquisition by Corona Remedies from multinational corporations
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Subscribe To Our Newsletter & Stay Updated
